<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3381">
  <stage>Registered</stage>
  <submitdate>23/11/2011</submitdate>
  <approvaldate>23/11/2011</approvaldate>
  <nctid>NCT01483560</nctid>
  <trial_identification>
    <studytitle>REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)</studytitle>
    <scientifictitle>Phase 3 Study of Metformin in Adults With Type 1 Diabetes</scientifictitle>
    <utrn />
    <trialacronym>REMOVAL</trialacronym>
    <secondaryid>2011-000300-18</secondaryid>
    <secondaryid>GN10DI406</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus, Type 1</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Metformin
Treatment: drugs - Placebo

Experimental: Metformin - Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily

Placebo Comparator: Placebo - 


Treatment: drugs: Metformin
3 years treatment duration

Treatment: drugs: Placebo
3 years duration

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in averaged mean far wall common carotid artery IMT</outcome>
      <timepoint>0, 12 months, 24 months, 36 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in HbA1c</outcome>
      <timepoint>Baseline, Year 1, Year 2, Year 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in LDL Cholesterol</outcome>
      <timepoint>Baseline, Year 1, Year 2, Year 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in albuminuria &amp; estimated glomerular filtration rate - Number of participants developing new microalbuminuria; change in absolute concentration</outcome>
      <timepoint>Baseline, Year 1, Year 2, Year 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in retinopathy stage - ETDRS grade</outcome>
      <timepoint>Baseline, Year 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in weight</outcome>
      <timepoint>Baseline, Year 1, Year 2, Year 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in insulin dose</outcome>
      <timepoint>Baseline, Year 1, Year 2, Year 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in endothelial function - RHI units</outcome>
      <timepoint>Baseline, Year 1, Year 3</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Type 1 Diabetes for five years or more*

          -  Age 40 years or above

          -  7.0 =&lt; HbA1c &lt;10.0% (53 - 86 mmol/mol)

        AND 3 or more of the following ten CVD risk factors:

          -  BMI &gt;27 kg/m^2

          -  Current HbA1c &gt;8.0% (64 mmol/mol)

          -  Known CVD/peripheral vascular disease

          -  Current smoker

          -  Estimated glomerular filtration rate &lt;90 ml/min per 1.73 m^3

          -  Confirmed micro- or macroalbuminuria [according to local assays and reference ranges]

          -  Hypertension (BP &gt;=140/90mmHg or established on antihypertensive treatment)

          -  Dyslipidaemia [total cholesterol &gt;=5.0 mmol/L (200 mg/dL);OR HDL cholesterol &lt;1.20
             mmol/L (46mg/dL) [MEN]; OR &lt;1.30 mmol/L (50 mg/dL) [WOMEN]; or triglycerides &gt;=1.7
             mmol/L (150mg/dL); or established on lipid-lowering treatment)]

          -  Strong family history of CVD (at least one parent, biological aunt/ uncle, or sibling
             with myocardial infarction or stroke aged &lt;60 years)

          -  Duration of diabetes &gt; 20 years</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  eGFR &lt; 45 ml/min/1.73m2

          -  woman of childbearing age not on effective contraception

          -  Pregnancy and/or lactation

          -  Acute coronary syndrome or Stroke/Transient Ischaemic Attack within the last three
             months

          -  NYHA stage 3 or 4 heart failure

          -  Significant hypoglycaemia unawareness

          -  Impaired cognitive function/ unable to give informed consent

          -  Previous carotid surgery/ inability to capture adequate carotid images

          -  Estimated glomerular filtration &lt; 45ml/min/1.73m^2 (MDRD)

          -  Gastroparesis

          -  History of lactic acidosis

          -  Other contraindications to metformin (hepatic impairment, known hypersensitivity to
             metformin, acute illness such as dehydration, severe infection, shock, acute cardiac
             failure or suspected tissue hypoxia)

          -  Any coexistent life threatening condition including prior diagnosis of cancer within
             two years

          -  History of alcohol problem or drug abuse</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>502</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>18/04/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Melbourne Hospital - Melbourne</hospital>
    <hospital>St Vincent's Hospital - Melbourne</hospital>
    <hospital>Royal Prince Albert Hospital - Sydney</hospital>
    <postcode> - Melbourne</postcode>
    <postcode> - Sydney</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ottawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Gentofte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastricht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Aberdeen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Ayr</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dundee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Durham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Exeter</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Gloucester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hull</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plymouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Salford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Glasgow</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>NHS Greater Glasgow and Clyde</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Juvenile Diabetes Research Foundation</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Imperial College London</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Wisconsin, Madison</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Dundee</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Merck Serono S.A., Geneva</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Itamar-Medical, Israel</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Western Ontario, Canada</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Melbourne</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Steno Diabetes Center</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Maastricht University Medical Center</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The trial is conducted in the UK, Australia, Canada, Denmark and the Netherlands. The aim is
      to test whether 3 years treatment with metformin added to titrated insulin therapy (towards
      target HbA1c7.0%/53 mmol/mol) reduces atherosclerosis, as measured by progression of carotid
      IMT, in adults with confirmed type 1 diabetes aged 40 years and over at increased risk for
      cardiovascular disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01483560</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>John Petrie, Prof</name>
      <address>University of Glasgow</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>